-
Neuralstem could seek partner for Phase II depression small molecule; to develop stem cell therapy solo – CEO
Neuralstem’s President and CEO discusses neurogenic small molecule lead compound, NSI-189, commercialization strategy with global life sciences business intelligence group, BioPharm Insight. Garr notes a partnership commitment would require the full potential of NSI-189 as a neurogenic agent in all potential indications on a global basis. The company plans to file an IND in late summer or early 3Q14 to commence the NSI-189 Phase II clinical trial in major depressive disorder before year-end, with Dr. Maurizio Fava, professor of Psychiatry, Harvard Medical School, cited as likely to be the principal investigator.
Select media coverage in this website is provided for the information and convenience of the public, and is not intended to be all-encompassing nor an endorsement of the specific stories or media outlets.